Pharmacological properties of the novel anti-varicella-zoster virus bicyclic nucleoside analogues (BCNAs)

Jan Balzarini; Rebecca Sienaert; Lieve Naesens; Graciela Andreï; Robert Snoeck; André B. P. Kuilenburg; Andrea Brancale; De Clercq Erik; Christopher McGuigan

Related publications

Article2004

Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella—Zoster Virus (VZV)

Rebecca Sienaert, Lieve Naesens, Andrea Brancale, Antonella Carangio, Graciela Andreï, Robert Snoeck, André B. P. Kuilenburg, De Clercq Erik, Christopher McGuigan, Jan Balzarini

Article2003

Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella-Zoster Virus (VZV)

Rebecca Sienaert, Lieve Naesens, Andrea Brancale, Antonella Carangio, Graciela Andreï, Robert Snoeck, André B. P. Kuilenburg, De Clercq Erik, Christopher McGuigan, Jan Balzarini

Article2003

Characterization of varicella-zoster virus (VZV) mutants resistant to bicyclic pyrimidine nucleoside analogues (BCNAs)

Graciela Andreï, Ghislain Opdenakker, Jan Balzarini, De Clercq Erik, Christopher McGuigan, Robert Snoeck

Article2002

Susceptibilities of several drug-resistant varicella-zoster virus (VZV) strains to bicyclic pyrimidine nucleoside analogues (BCNAs)

Graciela Andreï, Rebecca Sienaert, Lieve Naesens, De Clercq Erik, Christopher McGuigan, Jan Balzarini, Robert Snoeck

Article2003

Interaction of the bicyclic nucleoside analogues (BCNAs) with human varicella-zoster virus (VZV) and simian varicella virus (SVV) thymidine kinase and VZV DNA polymerase

Rebecca Sienaert, Lieve Naesens, G Luoni, Michael W. Wathen, Wayne L. Gray, Graciela Andreï, Robert Snoeck, De Clercq Erik, Christopher McGuigan, Jan Balzarini

Pharmacological properties of the novel anti-varicella-zoster virus bicyclic nucleoside analogues (BCNAs)

Discussion(0)

Related publications

Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella—Zoster Virus (VZV)

Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella-Zoster Virus (VZV)

Characterization of varicella-zoster virus (VZV) mutants resistant to bicyclic pyrimidine nucleoside analogues (BCNAs)

Susceptibilities of several drug-resistant varicella-zoster virus (VZV) strains to bicyclic pyrimidine nucleoside analogues (BCNAs)

Interaction of the bicyclic nucleoside analogues (BCNAs) with human varicella-zoster virus (VZV) and simian varicella virus (SVV) thymidine kinase and VZV DNA polymerase